Supplemental Figures and Tables from A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Figure S1. A, pretreatment bone marrow samples were treated diluent (-) with 10 μM melphalan (+) for 6 h and analyzed by immmunoblotting for FANCD2, ubiquitinated FANCD2 (Ub-FANCD2) and, as a loading control, heat shock protein 90 (HSP90). Supplemental Figure S2. A, Aliquots of whole cell lysates containing 5 x 106 pretreatment marrow mononuclear cells from the indicated patients were subjected to SDS-PAGE and blotting for the indicated antigens (lanes 5-12). Supplemental Figure S3. A, PAR suppression in PBMCs at various veliparib dose levels as a function of times during therapy. B, PAR suppression in PBMCs at 2 hours post dosing on day 1 and its relationship to clinical response. C, PAR suppression as assessed in bone marrow aspirates. Supplemental Table S1. MPN-Associated Leukemia Characteristics Supplemental Table S2 Accumulation of γH2AX in Viable Peripheral Blood CD34+ Cells Following Veliparib Administration at 80 mg Twice Daily Relative to Pretreatment (Day 0) Levels of DNA Damage
Authors: Keith W. Pratz, Michelle A. Rudek, Ivana Gojo, Mark R. Litzow, Michael A. McDevitt, Jiuping Ji, Larry M. Karnitz, James G. Herman, Robert J. Kinders, B. Douglas Smith, Steven D. Gore, Hetty E. Carraway, Margaret M. Showel, Douglas E. Gladstone, Mark J. Levis, Hua-Ling Tsai, Gary Rosner, Alice Chen, Scott H. Kaufmann, Judith E. Karp
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362409699